Elevating the Standards of Care in Veterinary Oncology

In 2021, Anivive Launched Laverdia®-CA1 (verdinexor) the first-ever orally administered lymphoma treatment for dogs. Today, Anivive expands its service offerings by integrating Vidium’s cutting edge genomic technology and specialty pathology services.

Shaping the Future of Veterinary Medicine

We are applying precision medicine approaches across our R&D portfolio to deepen our understanding of pet disease, developing novel therapies and supporting the development of innovative diagnostic and screening tests to improve how we treat, monitor and in some cases prevent certain diseases.

Next-Generation Tumor Genotyping

Searchlight DNA® – The most informative canine cancer genomic diagnostic test available. Extensively validated, next-generation diagnostic test that identifies important mutations in 120 relevant cancer genes to aid in the diagnosis and prognosis of cancer and inform treatment decisions.

Specialty Pathology Services

We offer an extensive array of histopathology and cytology services specializing in oncopathology, dermapathology, osteopathology, gastrointestinal pathology, oral pathology, and equine reproductive pathology.

Genomics is changing our understanding of cancer

The way we diagnose and treat cancer in pets is evolving, thanks in large part to genomics and precision medicine. And Vidium stands ready to help veterinary teams move into the world of personalized, precision medicine. We combine genomic and molecular diagnostic testing with pathology, providing you with one trusted source for advanced diagnostics.

Our diagnostics leverage the latest science available to provide more information about your patient’s cancer. A better understanding of your patient’s cancer can guide your diagnosis and treatment planning, helping to advance the care of pets with cancer.

LEARN MORE

Sammy

mast cell tumor
mutations in KIT, MDR1, and VEGFR2

Daisy

lymphoma
mutations in TRAF3 and PTEN

Bob

oral melanoma
mutations in KIT, MDM2, and NRAS

Luna

histiocytic sarcoma
mutations in PTPN11 and TP53

Sanford

lung adenocarcinoma
mutation in HER2

Our Diagnostic

Searchlightdna

Specialty Pathology Services

Our flagship test, SearchLight DNA, is an extensively validated, next-generation diagnostic test that checks for 120 relevant cancer genes, making it the most informative and scientifically rigorous canine cancer genetic test available.

LEARN MORE

Specialty Pathology Services

Our specialty pathology team combines extensive expertise in cancer pathology with genomic diagnostics to provide unparalleled advanced cancer diagnostic evaluation for your patients.

LEARN MORE

Guiding your team

At Vidium, our number one goal is to help guide you and your veterinary team through the challenges of managing your patients’ cancer diagnosis. As a company led by veterinarians, we consider ourselves part of the wider animal health team. We understand that genetics, genomics, transcriptomics, and proteomics are complicated. Our team not only understands the science, but also understands that it is our responsibility to deliver that science in a way that is clear, understandable, and actionable. We’re always available to discuss a case or a report and appreciate the opportunity to do so.

REQUEST A CONSULTATION

Who’s ready for the future of pet cancer treatment and prevention?

Join Vidium to deliver a new level of precision veterinary medicine

Get started

Life-saving statistics

50%

50% of dogs over the age of 10 develop cancer at some point.

Basset Hound Photo

80%

Osteosarcoma accounts for approximately 80% of the primary bone cancers found in dogs and is one of the most common cancer types in canines.

Cocker Photo

20%

Lymphoma is one of the most common cancers seen in dogs, accounting for 20% of all canine cancers.

Husky Photo

6 Million

More dogs (6 million) than humans (1.8 million) will be diagnosed with cancer this year in the United States.

Stats Dog1 2

94%

Around 94% of the cancer genome is arranged analogously to the human (genome).

Golden Retriever Phptp

1 in 4

1 in 4 dogs will be diagnosed with cancer during their lifetime.

Dog 4

Get started

Backed by TGen

The Translational Genomics Research Institute (TGen, an affiliate of City of Hope) is a leader in the genomics revolution. Begun by Dr. Jeffrey M. Trent, the founding Scientific Director of the Human Genome Project, this world-class research institute explores the most advanced areas of genetics in human and animal health. From our early beginnings with TGen, Vidium Animal Health^® benefits from the incredible knowledge and research of TGen scientists.

Learn More

For pet owners

Cancer is scary. After a cancer diagnosis in our pets, we often feel lost and alone. Vidium’s mission is to bring the incredible advances happening in human oncology precision medicine to our beloved pets. Starting with our formative relationship with the Translational Genomics Research Institute (TGen, an affiliate of City of Hope), a leader at the cutting edge of precision medicine, building on our discoveries in canine cancer genetics, and continuing with our rigorous scientific validation of diagnostic assays. Talk to your veterinary team about whether a SearchLight DNA test or a SpotLight ePARR test may be good options for your pet.

TELL ME MORE